【摘要】 目的 :观察欧耐特 (重组人白细胞介素 - 2 )胸腹腔内注射治疗恶性胸腹水的疗效和副作用。方法 :自 1996年 3月至 1998年 5月 ,对 2 4例恶性胸腹水患者 (其中 11例为恶性胸腔积液 ,13例为恶性腹腔积液 ) ,采用北京中化生物技术有限公司研制的欧耐特 (rhIl- 2 )胸腹腔内注射法进行疗效观察。尽量抽尽胸腹水后 ,胸腔内每次注入欧耐特2 0 0万U ,腹腔内每次注入 2 0 0～ 40 0万U ,注射 1～ 2次 /W ,连用 2～ 3周 ,1个月后观察疗效和毒副作用。结果 :欧耐特对恶性胸腔积液的有效率为 72 .7% (8/11) ,对恶性腹腔积液的有效率为 6 1.5 % (8/13) ,主要不良反应为发热 ,对血象及肝肾功能无明显影响。结论 :欧耐特治疗恶性胸腹水 ,疗效确切 ,毒副作用轻 ,值得在临床上推广应用。更多还原

【Abstract】 Objective:To evaluate the therapeutic effects of Ounait (rhIL-2) in the treatment of malignant pleural effusion or ascites. Methods: From March 1996 to May 1998, we have used Ounaite to treat 11 cases of malignant pleural effusion and 13 cases of malignant ascites. A dose of 2 X 106 u of Ounaite was injected intrapleurally and 2×10 6～4×10 6 u of Ounaite intraperitoneally to the patients with malignant pleural effusion and ascites respectively. The above dosage was given 1-2 times/w for 2-3 weeks, and then the effect and side-effects were observed. Results: The effective rates of malignant pleural effusion and ascites were 72.7%(8/11) and 61.5%(8/13) respectively. The chief side effect was pyrexia and no toxicity was observed on blood picture liver orkidney functions. Conclusion: Ounaite is effective in the treatment of malignant pleural effusion or ascites.更多还原